

PATENT
ATTORNEY DOCKET NO. 07588/026003

Certificate of Mailing	
Date of Deposit: <u>1/15/04</u>	Label Number: <u>EV 320806536 US</u>
I hereby certify under 37 C.F.R. § 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
<u>Elvis De La Cruz</u> Printed name of person mailing correspondence	<u>[Signature]</u> Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Peter Wernet	Art Unit:	Not yet assigned
Serial No.:	Not yet assigned	Examiner:	Not yet assigned
Filed:	January 15, 2004	Customer No.:	21559
Title:	HUMAN CORD BLOOD DERIVED UNRESTRICTED SOMATIC STEM CELLS (USSC)		

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PRELIMINARY AMENDMENT

Prior to examination of the above-captioned application, kindly amend the application as follows.

In the Specification:

Kindly amend the specification on page 23 as follows:

name	5'primer sequence	3'primer sequence	bp
PDGFR alpha	<u>acagtggagattacgaatgtg</u> (SEQ ID NO: 1)	<u>cacarcagtggatctcag</u> (SEQ ID NO: 2)	251
IGFR	<u>cgagtggagaaatctgcgg</u> (SEQ ID NO: 3)	<u>gaccagggcgtagttgtag</u> (SEQ ID NO: 4)	272
EGFR	<u>tgccacaaccagtgtgct</u> (SEQ ID NO: 5)	<u>ccacataattacggggacac</u> (SEQ ID NO: 6)	205
Neurofilament	<u>attcgcgcgagcttgaag</u> (SEQ ID NO: 7)	<u>cctggtaggaggcaatgtc</u> (SEQ ID NO: 8)	265
GFAP	<u>ctctccctggctcgaatgc</u> (SEQ ID NO: 9)	<u>cctctgataactggccg</u> (SEQ ID NO: 10)	871
Synaptophysin	<u>cctgcagaacaagtaccgag</u> (SEQ ID NO: 11)	<u>ccttgctgcccatagtcgc</u> (SEQ ID NO: 12)	516
Tyrosine hydroxylase	<u>caccttcgcgagttctcg</u> (SEQ ID NO: 13)	<u>ctgtccagcacgtcgatgg</u> (SEQ ID NO: 14)	387
YB1	<u>ggtgaggaggcagcaaagt</u> (SEQ ID NO: 15)	<u>agggttggaatactgtggtc</u> (SEQ ID NO: 16)	279
Runx1	<u>gcaagctgaggagcggcg</u> (SEQ ID NO: 17)	<u>gaccgacaaacctgaagtc</u> (SEQ ID NO: 18)	296
AML1c	<u>cagtgcctcatgagagaatgc</u> (SEQ ID NO: 19)	<u>gaccgacaaacctgaagtc</u> (SEQ ID NO: 20)	453
Cart-1	<u>ggagacgctggacaatgag</u> (SEQ ID NO: 21)	<u>ggtagctgtcagtccttggc</u> (SEQ ID NO: 22)	560
CD105	<u>cctgccactggacacagg</u> (SEQ ID NO: 23)	<u>atggcagctctgtggtgttg</u> (SEQ ID NO: 24)	411
Collagen Typ I	<u>ggacacaatggattgcaagg</u> (SEQ ID NO: 25)	<u>aacctgctccactctgg</u> (SEQ ID NO: 26)	441
Collagen Typ II	<u>tttcccaggtcaagatggtc</u> (SEQ ID NO: 27)	<u>cttcagcacctgtctcacca</u> (SEQ ID NO: 28)	377
Osteocalcin	<u>agtccagcaaaggtgcagc</u> (SEQ ID NO: 29)	<u>ggccgtagaagcgccgat</u> (SEQ ID NO: 30)	231
alkaline phosphatase	<u>gcttcagaagctcaacacca</u> (SEQ ID NO: 31)	<u>cgttgtctgagtaccagtcc</u> (SEQ ID NO: 32)	454
beta actin	<u>gagaaaatcttgcaccacac</u> (SEQ ID NO: 33)	<u>ctcggtaggatcttcat</u> (SEQ ID NO: 34)	340